...
首页> 外文期刊>Therapeutic advances in neurological disorders. >Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
【24h】

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

机译:作者回复:对具有高疗效疾病修饰治疗的多发性硬化患者对Covid-19 mRNA疫苗的对应对患者的对应性免疫反应

获取原文
           

摘要

We read the letter by Piquet, Corboy, and Vollmerrelated to our recent paper on the humoralimmune response to COVID-19 mRNA vaccinein patients with multiple sclerosis treated withhigh-efficacy disease-modifying therapies,1 butdid not find any relevant data they provide tosupport their criticism, except for theoreticalconsiderations.
机译:我们阅读了Piquet,Corboy和Vollmerrelated对我们最近的垃圾桶的纸张对Covid-19 mRNA疫苗患者进行了多发性硬化疾病修饰治疗,1个BUTDID没有找到任何相关数据,他们提供了他们提供的批评。 ,除理论外。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号